COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.

Autor:	Al-Kuraishy HM; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq., Al-Gareeb AI; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq., Al-Niemi MS; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Farahedi University, Baghdad, Iraq., Al-Buhadily AK; Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq., Al-Harchan NA; Department of Clinical Pharmacology, College of Dentistry, Al-Rasheed University, Baghdad, Iraq., Lugnier C; Department EA 3072 'Mitochondria, Oxidative Stress and Muscular Protection', Institute of Physiology, Faculty of Medicine, Strasbourg Cedex, France.
Jazyk:	angličtina
Zdroj:	Journal of microscopy and ultrastructure [J Microsc Ultrastruct] 2020 Dec 10; Vol. 8 (4), pp. 141-145. Date of Electronic Publication: 2020 Dec 10 (Print Publication: 2020).
DOI:	10.4103/JMAU.JMAU_63_20
Abstrakt:	COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels. Competing Interests: There are no conflicts of interest. (Copyright: © 2020 Journal of Microscopy and Ultrastructure.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu